Similar articles

• Targeted therapy in cancer and transgenic animal model.

  Inui A. Inui A. Cancer Invest. 2003;21(5):819-20. doi: 10.1081/cnv-120023783. Cancer Invest. 2003. PMID: 14628441 No abstract available.
• [Molecular target therapy for malignant tumors].

  [No authors listed] [No authors listed] Nihon Naika Gakkai Zasshi. 2005 Feb 20;94 Suppl:76-80. Nihon Naika Gakkai Zasshi. 2005. PMID: 15796061 Review. Japanese. No abstract available.
• [Molecular therapy of breast carcinoma in the advanced phase].

  Foggi P, Amodio A. Foggi P, et al. Tumori. 2003 Jul-Aug;89(4 Suppl):189-91. Tumori. 2003. PMID: 12903589 Review. Italian.
• [Problems in the current target therapy of malignancies].

  Stukov AN, Gershanovich ML, Filov VA, Imianitov EN. Stukov AN, et al. Vopr Onkol. 2005;51(5):607-11. Vopr Onkol. 2005. PMID: 16756022 Review. Russian. No abstract available.
• Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab.

  Pierobon M, Silvestri A, Spira A, Reeder A, Pin E, Banks S, Parasido E, Edmiston K, Liotta L, Petricoin E. Pierobon M, et al. J Proteome Res. 2014 Jun 6;13(6):2846-55. doi: 10.1021/pr401267m. Epub 2014 May 14. J Proteome Res. 2014. PMID: 24787230